Financhill
Sell
35

SRTS Quote, Financials, Valuation and Earnings

Last price:
$6.80
Seasonality move :
10.32%
Day range:
$6.79 - $7.11
52-week range:
$2.15 - $9.33
Dividend yield:
0%
P/E ratio:
11.93x
P/S ratio:
2.69x
P/B ratio:
2.06x
Volume:
255.3K
Avg. volume:
274K
1-year change:
167.72%
Market cap:
$111.5M
Revenue:
$24.4M
EPS (TTM):
$0.57

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SRTS
Sensus Healthcare
$5.9M -$0.02 -17.97% -56.41% --
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% $16.15
INFU
InfuSystems Holdings
$34.5M $0.05 9.85% 1713.24% --
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SRTS
Sensus Healthcare
$6.80 -- $111.5M 11.93x $0.00 0% 2.69x
CATX
Perspective Therapeutics
$3.25 $16.15 $219.7M -- $0.00 0% 17.55x
INFU
InfuSystems Holdings
$8.21 -- $174.6M 129.68x $0.00 0% 1.33x
RVP
Retractable Technologies
$0.64 -- $19.1M -- $0.00 0% 0.50x
VTAK
Catheter Precision
$0.38 -- $3M 0.43x $0.00 0% 1.01x
XTNT
Xtant Medical Holdings
$0.40 -- $55M -- $0.00 0% 0.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SRTS
Sensus Healthcare
-- 2.271 -- 7.59x
CATX
Perspective Therapeutics
-- -5.312 -- --
INFU
InfuSystems Holdings
33.51% 2.847 19.66% 1.37x
RVP
Retractable Technologies
1.55% 0.611 11.72% 5.80x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SRTS
Sensus Healthcare
$5.2M $1.5M 18.5% 18.5% 16.91% $3.6M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$19M $3.3M 1.77% 2.8% 9.23% $6.4M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Sensus Healthcare vs. Competitors

  • Which has Higher Returns SRTS or CATX?

    Perspective Therapeutics has a net margin of 13.75% compared to Sensus Healthcare's net margin of --. Sensus Healthcare's return on equity of 18.5% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SRTS
    Sensus Healthcare
    59.28% $0.07 $54.1M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About SRTS or CATX?

    Sensus Healthcare has a consensus price target of --, signalling upside risk potential of 69.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Sensus Healthcare, analysts believe Perspective Therapeutics is more attractive than Sensus Healthcare.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRTS
    Sensus Healthcare
    0 0 0
    CATX
    Perspective Therapeutics
    8 1 0
  • Is SRTS or CATX More Risky?

    Sensus Healthcare has a beta of 1.161, which suggesting that the stock is 16.139% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock SRTS or CATX?

    Sensus Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRTS or CATX?

    Sensus Healthcare quarterly revenues are $8.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Sensus Healthcare's net income of $1.2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Sensus Healthcare's price-to-earnings ratio is 11.93x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare is 2.69x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRTS
    Sensus Healthcare
    2.69x 11.93x $8.8M $1.2M
    CATX
    Perspective Therapeutics
    17.55x -- -- -$15.1M
  • Which has Higher Returns SRTS or INFU?

    InfuSystems Holdings has a net margin of 13.75% compared to Sensus Healthcare's net margin of 5.12%. Sensus Healthcare's return on equity of 18.5% beat InfuSystems Holdings's return on equity of 2.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRTS
    Sensus Healthcare
    59.28% $0.07 $54.1M
    INFU
    InfuSystems Holdings
    53.92% $0.08 $83.5M
  • What do Analysts Say About SRTS or INFU?

    Sensus Healthcare has a consensus price target of --, signalling upside risk potential of 69.12%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 72.05%. Given that InfuSystems Holdings has higher upside potential than Sensus Healthcare, analysts believe InfuSystems Holdings is more attractive than Sensus Healthcare.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRTS
    Sensus Healthcare
    0 0 0
    INFU
    InfuSystems Holdings
    0 0 0
  • Is SRTS or INFU More Risky?

    Sensus Healthcare has a beta of 1.161, which suggesting that the stock is 16.139% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

  • Which is a Better Dividend Stock SRTS or INFU?

    Sensus Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRTS or INFU?

    Sensus Healthcare quarterly revenues are $8.8M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Sensus Healthcare's net income of $1.2M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Sensus Healthcare's price-to-earnings ratio is 11.93x while InfuSystems Holdings's PE ratio is 129.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare is 2.69x versus 1.33x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRTS
    Sensus Healthcare
    2.69x 11.93x $8.8M $1.2M
    INFU
    InfuSystems Holdings
    1.33x 129.68x $35.3M $1.8M
  • Which has Higher Returns SRTS or RVP?

    Retractable Technologies has a net margin of 13.75% compared to Sensus Healthcare's net margin of -18.58%. Sensus Healthcare's return on equity of 18.5% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRTS
    Sensus Healthcare
    59.28% $0.07 $54.1M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About SRTS or RVP?

    Sensus Healthcare has a consensus price target of --, signalling upside risk potential of 69.12%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Sensus Healthcare has higher upside potential than Retractable Technologies, analysts believe Sensus Healthcare is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRTS
    Sensus Healthcare
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is SRTS or RVP More Risky?

    Sensus Healthcare has a beta of 1.161, which suggesting that the stock is 16.139% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

  • Which is a Better Dividend Stock SRTS or RVP?

    Sensus Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios SRTS or RVP?

    Sensus Healthcare quarterly revenues are $8.8M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Sensus Healthcare's net income of $1.2M is higher than Retractable Technologies's net income of -$1.9M. Notably, Sensus Healthcare's price-to-earnings ratio is 11.93x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare is 2.69x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRTS
    Sensus Healthcare
    2.69x 11.93x $8.8M $1.2M
    RVP
    Retractable Technologies
    0.50x -- $10.3M -$1.9M
  • Which has Higher Returns SRTS or VTAK?

    Catheter Precision has a net margin of 13.75% compared to Sensus Healthcare's net margin of -4291.67%. Sensus Healthcare's return on equity of 18.5% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRTS
    Sensus Healthcare
    59.28% $0.07 $54.1M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About SRTS or VTAK?

    Sensus Healthcare has a consensus price target of --, signalling upside risk potential of 69.12%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Sensus Healthcare, analysts believe Catheter Precision is more attractive than Sensus Healthcare.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRTS
    Sensus Healthcare
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is SRTS or VTAK More Risky?

    Sensus Healthcare has a beta of 1.161, which suggesting that the stock is 16.139% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock SRTS or VTAK?

    Sensus Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRTS or VTAK?

    Sensus Healthcare quarterly revenues are $8.8M, which are larger than Catheter Precision quarterly revenues of $96K. Sensus Healthcare's net income of $1.2M is higher than Catheter Precision's net income of -$4.1M. Notably, Sensus Healthcare's price-to-earnings ratio is 11.93x while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare is 2.69x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRTS
    Sensus Healthcare
    2.69x 11.93x $8.8M $1.2M
    VTAK
    Catheter Precision
    1.01x 0.43x $96K -$4.1M
  • Which has Higher Returns SRTS or XTNT?

    Xtant Medical Holdings has a net margin of 13.75% compared to Sensus Healthcare's net margin of -17.98%. Sensus Healthcare's return on equity of 18.5% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRTS
    Sensus Healthcare
    59.28% $0.07 $54.1M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About SRTS or XTNT?

    Sensus Healthcare has a consensus price target of --, signalling upside risk potential of 69.12%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Sensus Healthcare, analysts believe Xtant Medical Holdings is more attractive than Sensus Healthcare.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRTS
    Sensus Healthcare
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is SRTS or XTNT More Risky?

    Sensus Healthcare has a beta of 1.161, which suggesting that the stock is 16.139% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock SRTS or XTNT?

    Sensus Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRTS or XTNT?

    Sensus Healthcare quarterly revenues are $8.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Sensus Healthcare's net income of $1.2M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Sensus Healthcare's price-to-earnings ratio is 11.93x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare is 2.69x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRTS
    Sensus Healthcare
    2.69x 11.93x $8.8M $1.2M
    XTNT
    Xtant Medical Holdings
    0.46x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 25

Power Solutions International [PSIX] is up 27.42% over the past day.

Buy
65
TSLL alert for Dec 25

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
75
SMLR alert for Dec 25

Semler Scientific [SMLR] is up 15.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock